目的 探讨甲磺酸阿帕替尼片联合DP方案（多西他赛注射液+顺铂注射液）治疗晚期卵巢癌的临床疗效。方法 选择2016年1月—2018年1月宜昌市第二人民医院收治的78例晚期卵巢癌患者作为研究对象，按照随机数字表法将患者分为对照组和治疗组，每组各39例。对照组患者给予DP方案，第1天静脉滴注多西他赛注射液75 mg/m²，滴注完毕后，在B超引导下对患者腹腔进行穿刺，经导管注入60 mg顺铂注射液和1 800 mL生理盐水，液体温度控制在45℃左右，灌注完毕后，每隔15分钟帮助患者更换1次体位。治疗组在对照组治疗的基础上口服甲磺酸阿帕替尼片，1片/次，1次/d。1个化疗周期共21 d，两组患者共治疗3个化疗周期。观察两组的近期疗效，比较两组患者治疗前后的癌因性疼痛评分、癌因性疲乏评分、生存质量评分和血清肿瘤标记物指标。结果 治疗后，治疗组总有效率为92.31%，显著高于对照组的74.36%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者静息疼痛评分、运动疼痛评分均显著降低，癌因性疲乏评分显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组静息疼痛评分、运动疼痛评分明显低于对照组，癌因性疲乏评分明显高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者生理健康、精神健康、社会功能、总体感觉评分均显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组各项生存质量评分明显高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者癌胚抗原（CEA）、糖类抗原125（CA125）、糖类抗原153（CA153）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组血清肿瘤标记物水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 甲磺酸阿帕替尼片联合DP方案治疗晚期卵巢癌具有较好的临床疗效，可缓解癌因性疼痛和疲乏状况，改善患者生存质量，降低血清肿瘤标记物水平，且不良反应较少，具有较好的临床推广应用价值。

Objective To investigate the clinical efficacy of Apatinib Mesylate Tablets combined with DP regime (Docetaxel Injection and Cisplatin Injection) in treatment of advanced ovarian cancer. Methods Patients (78 cases) with advanced ovarian cancer in The Second People's Hospital of Yichang from January 2016 to January 2018 were randomly divided into control and treatment groups, and each group had 39 cases. Patients in the control group were given DP regime, and were iv administered with Docetaxel Injection 75 mg/m² at the first day. After the drip was completed, the intraperitoneal puncture was completed under the guidance of B-mode ultrasound, and 60 mg Cisplatin Injection and 1 800 mL saline were also injected by the catheter. The liquid temperature was controlled at about 45℃. After the infusion, patients were helped to change positions every 15 min. Patients in the treatment group were po administered with Apatinib Mesylate Tablets on the basis of control group, 1 tablet/time, once daily. One chemotherapy cycle lasted 21 d, and patients in the two groups were treated for three chemotherapy cycles. After treatment, the short-term efficacy were evaluated, and cancer-related pain scores, cancer-related fatigue scores, quality of life scores, and serum tumor markers levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 92.31%, which was significantly higher than 74.36% in the control group, and there were differences between two groups (P<0.05). After treatment, resting pain score and exercise pain score in two groups were significantly decreased, but cancer-related fatigue score was significantly increased, and there were differences in the same group (P<0.05). After treatment, resting pain score and exercise pain score in the treatment group were significantly lower than those in the control group, but cancer-related fatigue score was higher than that in the control group, and there were differences between two groups (P<0.05). After treatment, the scores of physical health, mental health, social function, and general sensation in two groups were significantly increased, and there were differences in the same group (P<0.05). After treatment, the quality of life scores in the treatment group were significantly higher than those in the control group, and there were differences between two groups (P<0.05). After treatment, the levels of CEA, CA125, and CA153 in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, serum tumor markers levels in the treatment group were significantly lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Apatinib Mesylate Tablets combined with DP regime has good clinical efficacy in treatment of advanced ovarian cancer, can alleviate cancer-related pain and fatigue, improve the quality of life, and reduce the level of serum tumor markers, and less adverse reactions, which has a certain clinical application value.